000142209 001__ 142209
000142209 005__ 20240229105147.0
000142209 0247_ $$2doi$$a10.1164/rccm.201708-1707OC
000142209 0247_ $$2pmid$$apmid:29617574
000142209 0247_ $$2ISSN$$a0003-0805
000142209 0247_ $$2ISSN$$a1073-449X
000142209 0247_ $$2ISSN$$a1535-4970
000142209 0247_ $$2ISSN$$a2376-3752
000142209 0247_ $$2altmetric$$aaltmetric:35724376
000142209 037__ $$aDKFZ-2019-00023
000142209 041__ $$aeng
000142209 082__ $$a610
000142209 1001_ $$aYamauchi, Yoshikane$$b0
000142209 245__ $$aCirculating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.
000142209 260__ $$aNew York, NY$$bAmerican Thoracic Society$$c2018
000142209 3367_ $$2DRIVER$$aarticle
000142209 3367_ $$2DataCite$$aOutput Types/Journal article
000142209 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1660215846_9237
000142209 3367_ $$2BibTeX$$aARTICLE
000142209 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000142209 3367_ $$00$$2EndNote$$aJournal Article
000142209 520__ $$aMyeloid-derived suppressor cell (MDSC) expansion has been found to play a role in disease progression in patients with cancer. However, the characteristics of MDSCs in lung cancer are poorly understood.We prospectively investigated MDSCs and inflammatory factors in tumor and peripheral blood samples from patients with resectable non-small cell lung cancer and studied their correlations with the disease prognosis.A complex analysis of MDSC subsets and inflammatory mediators was performed using flow cytometry and a Bio-Plex assay.A significant increase in the frequency of circulating monocytic (M)-MDSCs was observed in the patients with non-small cell lung cancer compared with the healthy donors (HDs). Moreover, the frequencies of M- and polymorphonuclear (PMN)-MDSCs were higher in tumors than in the peripheral blood of the same patients. This accumulation was associated with elevated concentrations of inflammatory mediators involved in MDSC migration to and activation in the tumor microenvironment. An analysis of the MDSC immunosuppressive pattern showed increased programmed death-ligand 1 expression on circulating cells from patients compared with HDs. Tumor PMN-MDSCs displayed higher programmed death-ligand 1 expression levels than the same cells in the peripheral blood. The frequency of CCR5 (C-C chemokine receptor 5) expression on circulating M-MDSCs was significantly higher in the patients than in the HDs. Clinical data analysis revealed negative correlations between recurrence-free survival and the frequencies of PMN-MDSCs and CCR5+ M-MDSCs in the circulation but not in tumors.Our findings suggest that the level of MDSCs in the peripheral blood but not in tumor tissues predicts recurrence after surgery.
000142209 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000142209 588__ $$aDataset connected to CrossRef, PubMed,
000142209 7001_ $$aSafi, Seyer$$b1
000142209 7001_ $$0P:(DE-He78)b7546a1fc8db4a83afc82a8bbd01e52b$$aBlattner, Carolin$$b2$$udkfz
000142209 7001_ $$0P:(DE-He78)a4d37cf08789986f17ff6ceb579e396e$$aRathinasamy, Anchana$$b3$$udkfz
000142209 7001_ $$0P:(DE-He78)d5882ffec9d5dea0104c7d33165e4a45$$aUmansky, Ludmila$$b4$$udkfz
000142209 7001_ $$aJuenger, Simone$$b5
000142209 7001_ $$aWarth, Arne$$b6
000142209 7001_ $$aEichhorn, Martin$$b7
000142209 7001_ $$aMuley, Thomas$$b8
000142209 7001_ $$aHerth, Felix J F$$b9
000142209 7001_ $$aDienemann, Hendrik$$b10
000142209 7001_ $$0P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aPlatten, Michael$$b11$$udkfz
000142209 7001_ $$0P:(DE-He78)1732377f6242a18280bc6aaa196988d1$$aBeckhove, Philipp$$b12$$udkfz
000142209 7001_ $$0P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aUtikal, Jochen$$b13$$udkfz
000142209 7001_ $$aHoffmann, Hans$$b14
000142209 7001_ $$0P:(DE-He78)38be34240daf8b47325afc7910e77f7b$$aUmansky, Viktor$$b15$$eLast author$$udkfz
000142209 773__ $$0PERI:(DE-600)1468352-0$$a10.1164/rccm.201708-1707OC$$gVol. 198, no. 6, p. 777 - 787$$n6$$p777 - 787$$tAmerican journal of respiratory and critical care medicine$$v198$$x1535-4970$$y2018
000142209 909CO $$ooai:inrepo02.dkfz.de:142209$$pVDB
000142209 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b7546a1fc8db4a83afc82a8bbd01e52b$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000142209 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a4d37cf08789986f17ff6ceb579e396e$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000142209 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d5882ffec9d5dea0104c7d33165e4a45$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000142209 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000142209 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1732377f6242a18280bc6aaa196988d1$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000142209 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a229f7724466e7efadf4a1ace1ff8af3$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000142209 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)38be34240daf8b47325afc7910e77f7b$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000142209 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000142209 9141_ $$y2018
000142209 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000142209 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000142209 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000142209 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000142209 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAM J RESP CRIT CARE : 2017
000142209 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000142209 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000142209 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000142209 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000142209 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000142209 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000142209 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000142209 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bAM J RESP CRIT CARE : 2017
000142209 9201_ $$0I:(DE-He78)D015-20160331$$kD015$$lTranslationale Immunologie$$x0
000142209 9201_ $$0I:(DE-He78)G300-20160331$$kG300$$lKKE Dermatoonkologie$$x1
000142209 9201_ $$0I:(DE-He78)G160-20160331$$kG160$$lNeuroimmunologie und Hirntumorimmunologie$$x2
000142209 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x3
000142209 980__ $$ajournal
000142209 980__ $$aVDB
000142209 980__ $$aI:(DE-He78)D015-20160331
000142209 980__ $$aI:(DE-He78)G300-20160331
000142209 980__ $$aI:(DE-He78)G160-20160331
000142209 980__ $$aI:(DE-He78)L101-20160331
000142209 980__ $$aUNRESTRICTED